Abuse-resistant drugs a growing niche

PharmTech.com notes that abuse-resistant pain drugs are a hot area of development right now. Author Patrician Van Arnum brings up Pfizer's recent $3.6 billion purchase of King Pharmaceuticals for its drug-delivery technology that discourages abuse of painkillers. The article provides a decent overview of King's pipeline of abuse-deterrent medication and the reason for Pfizer's interest. "King's leadership in new formulations of pain treatments designed to discourage common methods of misuse and abuse will provide Pfizer with multiple drug-delivery platforms while providing potential long-term upside," Pfizer said in a release in October. PharmTech's report

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.